NeuroMetrix maintains an active R&D program. Our strategy is to develop unique, proprietary medical devices that utilize non-invasive neurostimulation to diagnose and treat neurological conditions and pain. We seek to define new product categories and leapfrog existing technology. We develop products using our specialized in-house 10-person R&D team.

Diagnostics

Therapeutics

Quell® is currently indicated for symptomatic relief and management of chronic lower extremity pain. We are seeking to expand the FDA authorized clinical indications to include a number of chronic pain and neurological conditions with high prevalence and unmet treatment needs.

The use of Quell for fibromyalgia, CIPN and RLS is investigational only. The safety and effectiveness for these purposes has not been reviewed by the United States Food and Drug Administration (FDA).